105 related articles for article (PubMed ID: 18461287)
1. Stathmin expression in pheochromocytomas, paragangliomas, and in other endocrine tumors.
Sadow PM; Rumilla KM; Erickson LA; Lloyd RV
Endocr Pathol; 2008; 19(2):97-103. PubMed ID: 18461287
[TBL] [Abstract][Full Text] [Related]
2. A Guide to Pheochromocytomas and Paragangliomas.
Guilmette J; Sadow PM
Surg Pathol Clin; 2019 Dec; 12(4):951-965. PubMed ID: 31672301
[TBL] [Abstract][Full Text] [Related]
3. Molecular markers of paragangliomas/pheochromocytomas.
Zhikrivetskaya SO; Snezhkina AV; Zaretsky AR; Alekseev BY; Pokrovsky AV; Golovyuk AL; Melnikova NV; Stepanov OA; Kalinin DV; Moskalev AA; Krasnov GS; Dmitriev AA; Kudryavtseva AV
Oncotarget; 2017 Apr; 8(15):25756-25782. PubMed ID: 28187001
[TBL] [Abstract][Full Text] [Related]
4. Protocol for the examination of specimens from patients with pheochromocytomas and extra-adrenal paragangliomas.
Mete O; Tischler AS; de Krijger R; McNicol AM; Eisenhofer G; Pacak K; Ezzat S; Asa SL
Arch Pathol Lab Med; 2014 Feb; 138(2):182-8. PubMed ID: 24476517
[TBL] [Abstract][Full Text] [Related]
5. Novel alternative tools for metastatic pheochromocytomas/paragangliomas prediction.
Cui Y; Zhou Y; Gao Y; Ma X; Wang Y; Zhang X; Zhou T; Chen S; Lu L; Zhang Y; Chang X; Tong A; Li Y
J Endocrinol Invest; 2024 May; 47(5):1191-1203. PubMed ID: 38206552
[TBL] [Abstract][Full Text] [Related]
6. Anti-cancer potential of MAPK pathway inhibition in paragangliomas-effect of different statins on mouse pheochromocytoma cells.
Fliedner SM; Engel T; Lendvai NK; Shankavaram U; Nölting S; Wesley R; Elkahloun AG; Ungefroren H; Oldoerp A; Lampert G; Lehnert H; Timmers H; Pacak K
PLoS One; 2014; 9(5):e97712. PubMed ID: 24846270
[TBL] [Abstract][Full Text] [Related]
7. Supportive Management of Patients with Advanced Pheochromocytomas and Paragangliomas Receiving PRRT.
Tsang ES; Funk G; Leung J; Kalish G; Kennecke HF
Curr Oncol; 2021 Jul; 28(4):2823-2829. PubMed ID: 34436013
[TBL] [Abstract][Full Text] [Related]
8. Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific gene signature.
Martiniova L; Lai EW; Elkahloun AG; Abu-Asab M; Wickremasinghe A; Solis DC; Perera SM; Huynh TT; Lubensky IA; Tischler AS; Kvetnansky R; Alesci S; Morris JC; Pacak K
Clin Exp Metastasis; 2009; 26(3):239-50. PubMed ID: 19169894
[TBL] [Abstract][Full Text] [Related]
9. Pheochromocytoma and paraganglioma at a children's hospital in Argentina. A case series.
Deregibus MI; Pompozzi LA; Sansó G
Arch Argent Pediatr; 2024 Apr; 122(2):e202310099. PubMed ID: 37999372
[TBL] [Abstract][Full Text] [Related]
10. Perioperative Management of Pheochromocytomas and Sympathetic Paragangliomas.
Fagundes GFC; Almeida MQ
J Endocr Soc; 2022 Feb; 6(2):bvac004. PubMed ID: 35128297
[TBL] [Abstract][Full Text] [Related]
11. Potential Biomarkers of Metastasizing Paragangliomas and Pheochromocytomas.
Snezhkina A; Pavlov V; Dmitriev A; Melnikova N; Kudryavtseva A
Life (Basel); 2021 Nov; 11(11):. PubMed ID: 34833055
[TBL] [Abstract][Full Text] [Related]
12. [French recommendations for malignant pheochromocytomas and paragangliomas by the national ENDOCAN-COMETE network].
de la Fouchardière C; Haissaguerre M; Decaussin-Petrucci M; Renaudin K; Deschamps F; Mirallié E; Murez T; Pattou F; Rocher L; Savoie PH; Faron M; Taieb D; Tabarin A; Bertherat J; Gimenez-Roqueplo AP; Amar L; Baudin E; Libé R
Bull Cancer; 2023 Oct; 110(10):1063-1083. PubMed ID: 37573200
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Investigation of Angiogenesis, PASS Score and Immunohistochemical Factors in Risk Assessment of Malignancy for Paraganglioma and Pheochromocytoma.
Milinkovic M; Soldatovic I; Zivaljevic V; Bozic V; Zivotic M; Tatic S; Dundjerovic D
Diagnostics (Basel); 2024 Apr; 14(8):. PubMed ID: 38667494
[TBL] [Abstract][Full Text] [Related]
14. Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma.
Parenti G; Zampetti B; Rapizzi E; Ercolino T; Giachè V; Mannelli M
J Oncol; 2012; 2012():872713. PubMed ID: 22851969
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of stathmin promotes metastasis and growth of malignant solid tumors: a systemic review and meta-analysis.
Biaoxue R; Hua L; Wenlong G; Shuanying Y
Oncotarget; 2016 Nov; 7(48):78994-79007. PubMed ID: 27806343
[TBL] [Abstract][Full Text] [Related]
16. Stathmin is an Independent Prognostic Marker of Poor Outcome in Uterine Leiomyosarcoma.
Davidson B; Skeie-Jensen T; Holth A; Hausladen S
Int J Gynecol Pathol; 2024 Jun; ():. PubMed ID: 38847524
[TBL] [Abstract][Full Text] [Related]
17. Pitfalls in the Diagnostic Evaluation of Pheochromocytomas.
Fagundes GFC; Almeida MQ
J Endocr Soc; 2024 Apr; 8(6):bvae078. PubMed ID: 38737592
[TBL] [Abstract][Full Text] [Related]
18. Pheochromocytomas and paragangliomas: An opportunity to apply new advances for optimizing clinical management.
Curras-Freixes M; Salvador J
Rev Clin Esp; 2021 Jan; 221(1):30-32. PubMed ID: 32792088
[No Abstract] [Full Text] [Related]
19. Stathmin mediates neuroblastoma metastasis in a tubulin-independent manner via RhoA/ROCK signaling and enhanced transendothelial migration.
Fife CM; Sagnella SM; Teo WS; Po'uha ST; Byrne FL; Yeap YY; Ng DC; Davis TP; McCarroll JA; Kavallaris M
Oncogene; 2017 Jan; 36(4):501-511. PubMed ID: 27321182
[TBL] [Abstract][Full Text] [Related]
20. Stathmin in pancreatic neuroendocrine neoplasms: a marker of proliferation and PI3K signaling.
Schimmack S; Taylor A; Lawrence B; Schmitz-Winnenthal H; Fischer L; Büchler MW; Modlin IM; Kidd M; Tang LH
Tumour Biol; 2015 Jan; 36(1):399-408. PubMed ID: 25266798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
